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Abstract Development and (pre-) clinical assessment
were performed of a novel surgical tool for primary and
secondary tracheoesophageal puncture (TEP) with immedi-
ate voice prosthesis (VP) insertion in laryngectomized
patients, the Provox Vega Puncture Set (PVPS). After pre-
clinical assessment in fresh frozen cadavers, a multicenter
prospective clinical feasibility study in two stages was per-
formed. Stage-1 included 20 patients, and stage-2 had 27.
Based on observations in stage-1, the PVPS was re-
designed (decrease in diameter of the dilator from 23.5 to
18 Fr.) and further used in stage-2. Primary outcome mea-
sure was immediate VP insertion without requiring addi-
tional instruments. Secondary outcome measures for
comparison of the new with the traditional TEP procedure
were: appreciation, ease of use, time consumption, esti-
mated surgical risks and overall preference. A mini-max
two-stage study design was used to establish the required
sample size. In stage-1, dilatation forces were considered
too high in patients with a Wbrotic TE wall. With the Wnal
thinner version of the PVPS, VPs were successfully
inserted into the TEP in ‘one-go’ in 24/27 (89%) of TEPs:
20 primary and 7 secondary. Participating surgeons rated
appreciation, ease of use, time consumption and estimated
surgical risks as better. Related adverse events were few
and minor. The new PVPS appeared to be the preferred
device by all participating surgeons. This study shows that
the novel, disposable PVPS is a useful TEP instrument
allowing quick and easy insertion of the VP in the vast
majority of cases without requiring additional instruments.
Keywords Total laryngectomy · Tracheoesophageal 
puncture (TEP) · Voice prosthesis · Primary and secondary 
TEP · Seldinger technique
Introduction
Tracheoesophageal puncture (TEP) with immediate or
delayed implantation of a voice prosthesis (VP) presently is
the method of choice for restoring oral communication after
total laryngectomy (TLE) [1]. A VP is a one-way valve,
intended to prevent aspiration and to allow passage of pul-
monary air into the esophagus, which initiates mucosal
vibrations in the pharyngoesophageal segment and thus
sound [2]. This sound subsequently is further processed to
intelligible speech in the vocal tract.
The surgical procedure of VP implantation concerns a
straightforward TEP procedure, either primarily during
TLE or secondarily at a later stage. Secondary TEP was
introduced for the Wrst commercially available VP, the non-
indwelling ‘duckbill’ prosthesis, by Singer and Blom [3]. In
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venous catheter set to puncture the TE wall into the lumen
of a rigid esophagoscope and then used this intravenous
catheter to pull a dilating 14 Fr. red-rubber catheter into the
TEP. This second catheter was left in place for 7–10 days to
stabilize the TEP allowing a 16 Fr. VP to be inserted and
further maintained. This delayed insertion procedure was
necessary because the original duckbill prosthesis did not
contain an esophageal retention Xange and the retention
Xanges of the successor non-indwelling devices were too
thin to permit immediate insertion into the TEP. This was
diVerent for the Wrst indwelling device developed in 1980,
i.e., the ‘Groningen button’, which from the start was
intended to be an indwelling device, immediately inserted
at the TEP procedure, and therefore had a stable esophageal
and tracheal Xange [4]. In the Wrst paper describing this
indwelling device, immediate insertion without stenting of
the TEP appeared to be feasible in 19 patients during a pri-
mary procedure, and in 14 during a secondary procedure
[4].
Since then, primary TEP and immediate insertion of an
indwelling VP have been the preferred methods in many
European centers, also for other indwelling VPs developed
later, such as the Provox and the Nijdam prostheses [5–7].
The main reason for this preference is that immediate pros-
thesis insertion eliminates the need for temporary stenting
of the TEP with a catheter and allows for the earliest possi-
ble rehabilitation without the need for complicated prosthe-
sis sizing and Wtting at a later stage. At this stage, 10–
12 days postoperatively, the stoma site is still sore, the TEP
has not fully epithelialized yet, and the patients hardly have
recovered from the procedure. The psychological boost of
mostly instantaneous voicing, instead of voicing after a
cumbersome sizing and Wtting procedure, cannot be under-
estimated. Considering the relative ease of immediate VP
insertion in the TEP while the patient is under general anes-
thesia, there is actually no real valid argument anymore to
not immediately insert an indwelling device. Furthermore,
the low complication rate of this primary insertion has been
established in many clinical studies [7–10]. Also for the
Blom–Singer indwelling devices, the feasibility and advan-
tages of this approach recently have been recognized [11,
12].
Until present, the actual insertion of the indwelling
device after the TEP was mostly achieved by ‘delivering’
the tracheal Xange by pulling and rotating the VP into the
TEP with the help of two hemostats. Although this proce-
dure is not very complicated, it remains a delicate tech-
nique, which requires some force and time (somewhere
between 2 and 4 min) in which the patient is not ventilated.
Moreover, most of the current indwelling devices, such as
the recently developed third generation Provox Vega pros-
theses, are distributed with the necessary instruments for
anterograde replacement [13, 14], whereas immediate
insertion during TEP requires the availability of a separate
(dedicated or custom-made) guidewire. Therefore, a dedi-
cated set for primary and secondary VP insertion is prefera-
ble. Moreover, the TEP procedure itself mostly is carried
out with a special (Provox) trocar and cannula, or another
surgical instrument, which need sterilizing and regular
sharpening [5]. Therefore, a fully disposable set for imme-
diate (primary or secondary) VP insertion, eliminating the
need for additional instruments, could be helpful to further
facilitate this procedure. Since Seldinger techniques nowa-
days are often used to achieve the introduction of medical
devices by progressively dilating narrow puncture tracts,
e.g., tracheotomy tubes [15], using such a technique would
be an obvious choice. This paper describes the development
and subsequent clinical assessment of such a TEP and
immediate VP insertion tool in a prospective clinical multi-
center trial.
Materials, methods and patients
The newly developed Provox Vega Puncture Set (PVPS),
based on the Seldinger technique, is a fully disposable, ster-
ile set of instruments for primary and secondary TEP and
immediate VP insertion. The set consists of a curved punc-
ture needle to create the TEP, and a guidewire and a dilator
with a pre-mounted Provox Vega VP for the dilation of the
TEP and the actual introduction of the VP (see Fig. 1).
There is also a basic plastic pharynx protector added, only
to be used for primary TEP during TLE.
The Wrst diVerence with the present Provox TEP and
insertion method is that the needle is much sharper and
thinner (diameter 2.5 mm) than the tip and diameter (in
total 5 mm) of the Provox trocar and cannula mostly used
Fig. 1 Overview of the disposable Provox Vega Puncture Set; left the
pharynx protector (only to be used during primary TEP) and the guide-
wire; right the dilator (maximum diameter 18 Fr.) with the pre-loaded
Provox Vega voice prosthesis and the puncture needle with a diameter
of 2.5 mm123
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delivering the tracheal Xange through the TEP, a dilator is
used to progressively dilate the TEP tract and to deliver the
tracheal Xange through this tract into the tracheal lumen by
means of a special loop around the shaft of the VP. Details
of the needle and the loop are shown in Fig. 2.
In the PVPS, there is a guidewire, which is introduced
into the TEP through the puncture needle with the pharynx
protector still in place. After removal of the puncture nee-
dle and the pharynx protector, the guidewire is attached to
the dilator with a simple locking system, as shown in detail
in Fig. 3. The dilator itself is tapered with an increase in
diameter from 3 to 18 Fr., which enables progressive dilata-
tion of the TEP (the Seldinger principle). For the subse-
quent introduction of the VP into the TEP, the silicone loop
at the end of the dilator folds the tracheal Xange forward
due to the traction on the dilator. During the subsequent
narrow passage through the TEP, this loop slides over the
shaft of the VP and over the tracheal Xange, delivering and




The original diameter of the dilator of the PVPS was
25.5 Fr., based on the assumption that such a diameter was
required for uneventful delivering of the tracheal Xange of
the VP, which has an outer shaft diameter of 22.5 Fr. After
Fig. 2 a Details of the new 
puncture needle (on top) with a 
maximum diameter of 2.5 mm 
and the trocar part of the Provox 
trocar and cannula (maximum 
diameter 5 mm); note the clear 
diVerence in outer diameter and 
sharpness. b Details of the dila-
tor with the pre-loaded voice 
prosthesis and the special sili-
cone loop around the shaft of the 
VP for the delivery of the tra-
cheal Xange of the voice prosthe-
sis through the TEP tract
Fig. 3 Details of the use of the guidewire lock: the guidewire is passed
through the central lumen of the dilator (top-left) and the end of the
wire is placed in the opening next to this lumen (top-right); next, the
guidewire is pulled back (bottom-left) and securely locked into the
dilator (bottom-right)123
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be too large considering the forces needed to dilate the
TEP. Therefore, a smaller diameter (23.5 Fr.) was trialed,
and with that version the forces needed for dilatation in a
fresh frozen cadaver appeared to be more than halved.
Therefore, this version was deemed suitable for clinical
testing. After the inclusion of 20 patients (see below), the
decision was taken to suspend the clinical investigation,
since in two patients with a very Wbrotic TE party wall [post
(chemo)-radiotherapy], the dilatation forces were deemed
unacceptably high by the surgeon. Although the primary
outcome measure (successful insertion of the VP ‘in one-
go’, see below) was still met in these procedures, it was
decided to develop and trial smaller diameter versions of
the dilator, to reduce the dilatation resistance even further.
In subsequent cadaver testing with an 18 Fr. version, the
forces needed to adequately dilate the TEP appeared to be
reduced suYciently, whereas immediate insertion of the VP
still was feasible. Therefore, this 18 Fr. diameter dilator
was deemed appropriate and the clinical investigation was
restarted with this design (referred to as Stage 2 of this
trial).
Study design
Once pre-operatively the indication for primary or second-
ary prosthetic voice rehabilitation was established, patients
were informed about the use of the new TEP tool for VP
insertion. The institutional review board (IRB) of all partic-
ipating centers approved the study and a written informed
consent was obtained from all patients.
Prior to the application, all surgeons were instructed
about the proper use and order of handling of the PVPS,
and had the possibility to practice the procedure in a dedi-
cated tabletop model. Procedures were recorded on video
for later re-evaluation and/or timing of the TEP with the
PVPS. Immediately after completion of the procedure, data
collection consisted of a study-speciWc questionnaire
assessing each step of the procedure, registering possible
complications and deviations of the methodology (i.e., the
use of additional instruments such as hemostats), and over-
all physician satisfaction and preference. The structured
questions could be answered either on a four-point ‘scale’
(e.g., on the question “Did you have any diYculties dilating
the TE puncture?”, the possible answers were: 1 = not at
all; 2 = a little bit; 3 = quite a bit; 4 = very much), or on a
Wve-point ‘scale’ (e.g., on the question “Is the force needed
to create the puncture with the needle lower or higher than
the force needed to create the puncture with the Provox tro-
car and cannula?”, the possible answers were: 1 = much
lower; 2 = slightly lower; 3 = similar; 4 = slightly higher;
5 = much higher). Surgeons were also asked to estimate the
time they would have needed for the traditional Provox tro-
car and cannula method. Four weeks after the TEP proce-
dure, an oV-study form was completed, including
registration of any complications. All adverse events and
device eVects were recorded and reported to the IRB(s).
Patients
As mentioned before, a multicenter clinical assessment of
the PVPS was carried out in two stages. In the Wrst stage, 20
patients were included, 16 males and 4 females with a mean
age of 64.7 years (SD = 11.9; range 46–90). Nine patients
underwent primary TEP with immediate VP insertion dur-
ing the TLE, while 11 patients underwent a secondary TEP
procedure with the PVPS. In 16 patients, an 8-mm Provox
Vega was inserted, in 3 patients a 10-mm, and in one a
12.5-mm Provox Vega. All procedures were carried out
under general anesthesia. In ten patients, the indication for
TLE was recurrent disease after radiotherapy, of whom Wve
had received chemoradiotherapy, Wve patients had postop-
erative radiotherapy and Wve were not radiated.
In stage 2 (using the Wnal and actual design of the
PVPS), 23 male and four female patients were included in
the study, with a mean age of 62.0 years (SD = 7.8; range
46–78). Twenty patients underwent primary and seven sec-
ondary TEP with the 18 Fr. PVPS. The length of the VP
Fig. 4 Function of the introduction loop of the dilator. During the passage of the voice prosthesis through the TEP tract, the loop pulls the tracheal
Xange forward and delivers and unfolds it into the trachea when it is ‘stripped oV’ from the prosthesis shaft123
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patients. All procedures were carried out under general
anesthesia. In eight patients, the indication for TLE was
recurrent disease after radiotherapy, of whom four had che-
moradiotherapy. Ten patients had postoperative radiother-
apy, of whom two had chemoradiotherapy; nine patients
were not radiated.
In all patients, the length of the prosthesis to be inserted
was established by palpation of the thickness of the TE
wall, either bi-digitally during primary TEP, or by palpat-
ing the TE wall onto the intraluminal device (mostly a rigid
esophagoscope) during secondary TEP. All surgeons
involved had extensive experience with this in the tradi-
tional Provox trocar and cannula method. Patients were
entered in each center consecutively and, since in some
centers the protocol review process required more time than
expected, there were diVerences in contributions in the two
stages of the trial. Patient characteristics and center contri-
butions are provided in Table 1.
Outcome measures
The primary outcome measure was the immediate inser-
tion of the VP without the need of any additional instru-
ments. Secondary outcome measures were: appreciation
of the PVPS, ease of use of the new instrument set and
procedure, time needed for insertion in comparison to the
estimated time for the traditional Provox trocar and can-
nula method, the estimated surgical risk using the PVPS
and the overall preference for the new PVPS or the tradi-
tional method.
Statistics
To introduce the device safely, a two-stage design, allow-
ing for early stopping, with the following statistical consid-
erations was applied: calculation of the number of subjects
needed was based on an optimal mini-max design [16]. If
the successes for the primary outcome measure is less than
or equal to 70% (0=0.7), the device is considered not (yet)
suitable for implementation in clinical practice. If the per-
centage of successful insertions is 90% or more
(new = 0.9), it can be concluded that the device is suY-
ciently safe to use. Furthermore,  is set to 0.05 and 1-
(power) to 0.8. With the parameters set accordingly, the
sample size for the Wrst stage (nS1; ‘stop–go’ point) is 23
and at least 20 successful insertions need to be observed to
proceed to the next stage. If less or equal to 19 successes
are observed, the trial should stop due to failure of the
device. For the second stage, three additional patients have
to be enrolled. Overall, a minimum of 22/26 successes will
exclude with 95% certainty a success rate of 70% or worse
and thereby indicate that the device is successful.
Statistical analyses of the data are mainly descriptive and
include frequency tabulations, percentages and duration of
the procedure. When variables are compared, a Wilcoxon




In the Wrst stage, 18/20 of the PVPS procedures (90%)
resulted in immediate insertion of the VP, with only two
procedures requiring the additional use of two hemostats.
The mean recorded time needed for the new procedure was
shorter (110 s; SD = 8; range 60–224) than that estimated
for the Provox trocar and cannula method (201 s; SD 66;
range 90–360), a statistically signiWcant diVerence
(P < 0.0001).
Actual design of PVPS
In the second stage up to the ‘stop–go’ point, 20/23 PVPS
procedures were successful ‘in one-go’ (87%) and Wnally
24/27 resulted in immediate insertion of the VP (89%). In
two cases, two hemostats were used as additional instru-
ments to insert the VP to completely deliver the tracheal
Xange, and in one case three hemostats. The mean recorded
time needed for the trial procedure in the second stage was
shorter (155 s; SD 116; range 58–600) than that estimated
for the Provox trocar and cannula method (221 s; SD 58;
range 120–330), also a statistically signiWcant diVerence
Table 1 Patient characteristics
a
‘Stop–go’ assessment: N = 23 (20 insertions correct without addi-
tional instruments, 85%); go: N = 4 (all correct in one-go); two addi-
tionally included patients had to be excluded because of protocol
violation











Primary TEP 9 20
Secondary TEP 11 7123
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not diVerent (P = 0.115). In stage 2, there were two outliers
with 600 and 360 s, because of an unsuspected stenosis of
the pharynx, which required dilatation Wrst. Without those
outliers, the mean insertion time in stage 2 was 110 s with a
range of 58–224 s, and the mean insertion times for stage 1
and 2 were again not signiWcantly diVerent (P = 0.268). In
stage 2, there were no cases anymore in which the surgeons
considered the dilatation force unacceptably high, the rea-
son for the re-design in stage 1. In Table 2, the main results
are listed for both stages of the study.
As can be seen in Table 2 as well, in both stages the sur-
geons had a high appreciation for the new method and con-
sidered it easier to use than the traditional trocar and
cannula method. Also, the overall risk of the PVPS was
considered less in the majority of the procedures, leading to
an overall preference for the new TEP tool. The length of
the VP was judged correctly except in one case, where an
8-mm VP was implanted, which postoperatively needed re-
adjustment (see adverse events).
Assessment of the technical aspects of the new proce-
dure, i.e., the introduction of the pharynx protector in case
of primary TEP, the actual TEP with the disposable needle,
the introduction of the guidewire through the needle, the
subsequent removal of the needle and the pharynx protec-
tor, the passage of the guidewire through the dilator and
locking that into the slot, and the Wnal dilatation and the
actual introduction of the VP were considered trouble free
in the majority of cases. In stage 2, the PVPS was used
right-handed in 25 and left-handed in two cases, and all sur-
geons considered the new tool suitable for both approaches.
There were 27 instead of 26 patients included in the trial,
because at the end of the study simultaneous informed con-
sent was obtained from two patients on the same day (one
in Ulm and one in Barcelona).
Procedural inconsistencies
Inconsistent use of (elements of) the PVPS was rare.
There were two (2) cases of retrograde insertion of the
guidewire through the exposed tip of the needle, because
the dilator already had been attached. In another case,
the pharynx protector was not removed prior to attach-
ment of the dilator, which was corrected by releasing the
lock of the guidewire, removal of the pharynx protector
and reattachment of the dilator with subsequent unevent-
ful insertion of the VP. This latter error occurred in one
other case (primary TEP), but then the surgeon pulled
the VP through the pharynx protector, through which
maneuver the VP got detached from the loop unnoticed,
making the insertion with the PVPS impossible. This
case was considered a protocol violation. The TEP nev-
ertheless could be completed using the traditional two
hemostats to ‘deliver’ the tracheal Xange. A second pro-
tocol violation occurred in a patient, where the surgeon
indicated needing a PVPS with a pre-loaded 10-mm VP,
but when this appeared not to be available anymore, still
tried to insert an 8-mm device. This 8-mm VP turned out
to be too short for the tracheal Xange to be delivered
through the TEP by the loop. This case was solved using
a regular 10-mm VP with the traditional Provox trocar
and cannula method.
Table 2 Primary and secondary outcome parameter(s) for the evaluation of the Provox Vega Puncture Set (PVPS) in comparison with the tradi-
tional Provox trocar and cannula method (PTCM); + favoring PVPS; = PVPS equals PTCM; ¡ favoring PTCM; < easier/less time/less risk for
PVPS; > less easy/more time/risk for PVPS
a Mean PVPS time for stage 1 and 2 is not signiWcantly diVerent (P = 0.115)
b There were two outliers with 600 and 360 s, because of an unsuspected stenosis of the pharynx, which required dilatation Wrst. Without those
outliers, the mean PVPS time was 110 s with a range of 58–224 s. Mean PVPS time for stage 1 and 2 is again not signiWcantly diVerent (P = 0.268)
Stage 1 (N = 20) Stage 2 (N = 27)
Primary outcome measure
Insertion in ‘one-go’ 18 (90%) 24 (89%)
Extra instruments 18 none / 2 + 2 hemostats 24 none / 2 + 2 hemostats / 1 + 3 
hemostats
Secondary outcome measures
Mean time PVPSa 110 s (SD = 48; range 60–224) 155 s (SD = 116; range 58–600)b
Mean estimate PTCM 201 s (SD = 66; range 90–360); 
P · 0.0001
221 s (SD = 58; range 120–330); 
P = 0.002
Appreciation 18 + / 1 =/ 1 ¡ 25 + / 2 ¡
Ease of use 17 < / 2 =/ 1 > 26 < / 1 >
Time needed 16 < / 3 =/ 1 > 23 < / 3 =/1 >
Risk 14 < / 5 =/ 1 missing 20 < / 7 =
Preference 17 + / 3 ¡ 26 + / 1 ¡123
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In stage 1, there were four adverse events reported during
the observation period of 4 weeks, three of which were
deemed not to be related to the TEP procedure by the
responsible surgeon. These three included two primary TEP
patients developing postoperative wound infections outside
the TEP area, requiring pectoralis major Xap reconstruc-
tion, and one patient with pre-existing COPD developing
postoperative pneumonia, responding to conservative/anti-
biotic treatment. The fourth case concerned a secondary
TEP patient, who developed a peri-prosthetic leakage 2–
3 days postoperatively, resolving spontaneously within a
few days. This could be attributed to the wider dilator and
the Wbrosis present.
In stage 2, adverse events were reported in 8/27 patients,
most of which were deemed not to be related to the TEP
procedure. One patient developed tracheitis that responded
to antibiotic treatment. In a secondary TEP patient, a muco-
sal tearing occurred in the stenotic pharyngeal wall during
the rigid endoscopy procedure, but this did not interfere
with the subsequent PVPS use. Three primary TEP patients
developed postoperative Wstulas, and one a neck abscess,
all resolving by conservative measures. There were two
adverse events considered to be related to the procedure,
i.e., one case in which the prosthesis was too short and
retracted partly into the TEP tract. Subsequent reposition-
ing, however, solved this issue. In the other one, a second-
ary TEP case, the guidewire was passed outside the
endoluminal device, penetrating the posterior pharyngeal
wall. However, after discovering this, the guidewire was
pulled back and still could be passed through the scope cor-
rectly and the PVPS procedure could be completed as
intended. The patient had already received prophylactic
antibiotics, as usual, and no problems developed postopera-
tively.
Discussion
This development and subsequent multicenter clinical fea-
sibility study shows that the novel surgical tool for primary
and secondary TEP and immediate VP insertion based on
the Seldinger technique, PVPS, is a versatile and easy to
use instrument set, allowing immediate insertion of the VP
in some 90% of the cases without the need of additional
instruments. Although the estimated time gain is not very
long in relation to the total OR time, this diVerence can be
relevant, as during the TEP procedure, the patient is not
ventilated.
With respect to a possible learning curve, if any, it is
interesting to discuss in some more detail the few errors
that were observed. In two cases, the instrument was not
used appropriately. In one primary TEP, the pharynx pro-
tector was removed before introducing the guidewire, and
in a secondary TEP the guidewire was not caught in the
intraluminal device. As this guidewire is quite thin, it perfo-
rated the posterior esophageal wall. Fortunately, this had no
clinical consequences, since the instruments used were ster-
ile and the patient received standard prophylactic antibiot-
ics.
With respect to the palpation of the TE party wall, in
order to choose the correct VP length, there were very few
mistakes. In fact only in one case a too short prosthesis was
chosen, as mentioned under adverse events. This could be
corrected by readjusting the tracheal Xange and did not lead
to early replacement of the VP. It has to be reemphasized
that all surgeons participating in this trial had extensive
experience with the method of TEP and immediate VP
insertion, and this is certainly an important reason why in
almost all cases the optimal VP length was used. For sur-
geons with less experience with TEP and immediate VP
insertion, this might be diVerent, although from experience
with the traditional Provox TEP method, it is known that
the learning curve is short as well. The reason is that in the
vast majority of cases, the Wrst VP used does not need to be
longer than 8 mm (in this trial 39/47, 83%), and that only in
a minority of cases a 10-mm version (7/47, 15%) is
required, and exceptionally a 12.5-mm version (1/47, 2%)
[5, 7]. The latter two lengths are mainly needed in second-
ary TEP cases.
In the literature, several TEP techniques have been
described, all using some sort of a guidewire, either to
establish the TEP tract, and/or to immediately insert the
VP. Sometimes, this concerns the use of clinically readily
available tubes, such as the red rubber catheter originally
used by Singer and Blom [3]. Other times, this concerns
dedicated instruments, such as the Groningen TEP trocar
and Xexible metal guidewire with a screw tip to perform the
TEP and to attach and insert the VP [4]. Also, the original
Provox disposable guidewire is a dedicated device, further
simplifying the procedure [5]. More recently, Deschler
et al. [11, 12] demonstrated the usability and versatility of
this technique of primary TEP and immediate insertion of
the indwelling Blom–Singer VP, by placing the VP on the
tip of a 16 Fr. catheter and securing its strap with a silk
suture to the catheter. These latter two papers show that pri-
mary VP insertion, which is a common practice Europe, is
gaining popularity in the USA as well.
In conclusion, this prospective multicenter clinical feasi-
bility study in 47 patients shows that this novel disposable
tool for primary and secondary TEP and immediate VP
insertion based on the Seldinger technique, the PVPS, is a
useful instrument. It allows for immediate insertion of the
VP in almost 90% of the cases without requiring additional
instruments. The study showed a high degree of satisfaction123
262 Eur Arch Otorhinolaryngol (2013) 270:255–262with the PVPS and a substantial preference over the tradi-
tional Provox trocar and cannula method by the participat-
ing surgeons. This means that the PVPS can be considered
an interesting addition to the armamentarium of surgeons
already applying primary and secondary TEP with immedi-
ate VP insertion, but also that the PVPS can lower the
threshold for those surgeons, who still delay the VP inser-
tion after stenting the TEP tract with a catheter.
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